Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure raising its FY2024 consolidated revenue forecast from KRW 4.1564T to KRW 4.3411T, driven by successful ramp-up of Plant 4 utilization and favorable foreign exchange conditions.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) Forecast on Operating Results Based on Consolidated Financial Statements (Fair Disclosure)
- Original Filing Date: January 24, 2024
- Reason for Correction: Increase in revenue driven by successful ramp-up of Plant 4 utilization and sustained favorable exchange rate environment
- Key Correction Items:
- FY2024 Revenue Forecast: (Before) KRW 4,156.4B ➔ (After) KRW 4,341.1B
- Expected Revenue Growth Range: (Before) +10% to +15% YoY ➔ (After) +15% to +20% YoY
- Forecast Details (As Revised in Filing):
- Target Period: January 1, 2024 – December 31, 2024
- FY2024 Projected Revenue: KRW 4,341.1B (Midpoint of projected range)
- Basis for Forecast: Market outlook and business plans
- Information Provision Details:
- Provider: IR Team
- Target Audience: Domestic and foreign investors, etc.
- Date & Time: October 23, 2024
- Other Important Details:
- The FY2024 revenue figure represents the midpoint of the projected revenue range (+15% to +20% YoY).
- FY2024 operating profit margin is projected to decline by a low-single-digit amount compared with FY2023.
- Figures are forward-looking estimates based on business plans and actual results may differ depending on business environment and market conditions.
- Historical Forecast Accuracy (FY2023):
- Forecast: KRW 3,601.6B / Actual: KRW 3,694.6B / Error Rate: 2.6%
- Related Disclosure: January 24, 2024: Forecast on Operating Results Based on Consolidated Financial Statements (Fair Disclosure)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Upward Revenue Guidance Revision and Final FY Performance
This correction disclosure provides notice that the FY2024 annual revenue forecast has been revised upward to reflect 15%–20% YoY growth (midpoint KRW 4.3411T) due to Plant 4 ramp-up and FX tailwinds.
Tracking whether final full-year financial results align with the updated forecast range is essential.
Relevant developments can be verified in the upcoming FY2024 Annual Report and official year-end earnings disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
